Exceptional responders to abexinostat (ABX) plus pazopanib (PAZ) in pretreated renal cell carcinoma (RCC) and other solid tumors: Long-term follow-up of a phase 1b study.
2019
3022Background: We previously reported the initial phase 1b study results of PAZ + ABX, a potent pan-
HDAC inhibitor, demonstrating acceptable toxicity profile and encouraging anti-tumor activity (A...
Keywords:
-
Correction
-
Source
-
Cite
-
Save
-
Machine Reading By IdeaReader
0
References
2
Citations
NaN
KQI